[1] |
慎慧, 郭建, 张旻, 等. 上海地区临床分离念珠菌的耐药性监测[J]. 中国感染与化疗杂志, 2019,19(3):292⁃299. doi: 10. 16718/j.1009⁃7708.2019.03.013.
|
[2] |
Colombo AL, Júnior J, Guinea J. Emerging multidrug⁃resistant Candida species[J]. Curr Opin Infect Dis, 2017,30(6):528⁃538. doi: 10.1097/QCO.0000000000000411.
|
[3] |
Dufresne SF, Marr KA, Sydnor E, et al. Epidemiology of Candida kefyr in patients with hematologic malignancies[J]. J Clin Microbiol, 2014,52(6):1830⁃1837. doi: 10.1128/JCM.00131⁃14.
|
[4] |
Fekkar A, Meyer I, Brossas JY, et al. Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin[J]. Antimicrob Agents Chemother, 2013,57(5):2380⁃2382. doi: 10.1128/AAC.02037⁃12.
|
[5] |
Ahmad S, Khan Z, Al⁃Sweih N, et al. Candida auris in various hospitals across Kuwait and their susceptibility and molecular basis of resistance to antifungal drugs[J]. Mycoses, 2020,63(1):104⁃112. doi: 10.1111/myc.13022.
|
[6] |
Bretagne S, Renaudat C, Desnos⁃Ollivier M, et al. Predisposing factors and outcome of uncommon yeast species⁃related fungaemia based on an exhaustive surveillance programme (2002⁃14)[J]. J Antimicrob Chemother, 2017,72(6):1784⁃1793. doi: 10.1093/jac/dkx045.
|
[7] |
Clinical and Laboratory Standards Institute(CLSI). Performance standards for antifungal susceptibility testing of yeasts: CLSI M60[S]. Wayne, PA: CLSI, 2018.
|
[8] |
Clinical and Laboratory Standards Institute(CLSI). CLSI document M27⁃A3 reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard⁃third edition[S]. Wayne, PA: CLSI, 2008.
|
[9] |
Clinical and Laboratory Standards Institute(CLSI). CLSI supplement M59 epidemiological cutoff values for antifungal susceptibility testing; 3rd ed[S]. Wayne, PA: CLSI,2020.
|
[10] |
Dufresne SF, Marr KA, Sydnor E, et al. Epidemiology of Candida kefyr in patients with hematologic malignancies[J]. J Clin Microbiol, 2014,52(6):1830⁃1837. doi: 10.1128/JCM.00131⁃ 14.
|
[11] |
Montravers P, Mira JP, Gangneux JP, et al. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive⁃care units[J]. Clin Microbiol Infect, 2011,17(7):1061⁃1067. doi: 10.1111/j.1469⁃0691.2010.03360.x.
|
[12] |
Aldejohann AM, Theuersbacher J, Haug L, et al. First case of Kluyveromyces marxianus (Candida kefyr) late onset keratitis after lamellar endothelial corneal graft[J]. Med Mycol Case Rep, 2021,32:21⁃24. doi: 10.1016/j.mmcr.2021.02.001.
|
[13] |
Lortholary O, Renaudat C, Sitbon K, et al. The risk and clinical outcome of candidemia depending on underlying malignancy[J]. Intensive Care Med, 2017,43(5):652⁃662. doi: 10.1007/s00134⁃017⁃4743⁃y.
|
[14] |
Ahmad S, Khan Z, Al⁃Sweih N, et al. Candida kefyr in Kuwait: prevalence, antifungal drug susceptibility and genotypic heterogeneity[J/OL]. PLoS One, 2020,15(10):e0240426. doi: 10.1371/journal.pone.0240426.
|
[15] |
Diba K, Makhdoomi K, Nasri E, et al. Emerging Candida species isolated from renal transplant recipients: species distribution and susceptibility profiles[J]. Microb Pathog, 2018,125:240⁃245. doi: 10.1016/j.micpath.2018.09.026.
|
[16] |
Weichert S, Reinshagen K, Zahn K, et al. Candidiasis caused by Candida kefyr in a neonate: case report[J]. BMC Infect Dis, 2012,12:61. doi: 10.1186/1471⁃2334⁃12⁃61.
|
[17] |
Kalkanci A, Saracli MA, Guzel O, et al. Clustering of nosocomial Candida kefyr infections among hematological patients in a university hospital: molecular typing of the strains by PFGE and RAPD[J]. J Mycol Med, 2007,17(4):250255. doi: 10.1016/j.mycmed.2007.09.003.
|
[18] |
Karabıçak N, Alem N. Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species⁃specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance[J]. Mikrobiyol Bul, 2016,50(1):122⁃132. doi: 10.5578/mb.10682.
|
[19] |
Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty years of the SENTRY Antifungal Surveillance Program: results for Candida species from 1997⁃2016[J]. Open Forum Infect Dis, 2019,6(Suppl 1):S79⁃S94. doi: 10.1093/ofid/ofy358.
|
[20] |
Khan Z, Ahmad S, Al⁃Obaid K, et al. Candida kefyr as a cause of bloodstream infection and adjunctive role of biomarkers in its diagnosis[J]. J Mycol Med, 2015,25(1):71⁃75. doi: 10.1016/j.mycmed.2014.04.002.
|
[21] |
Jung DS, Farmakiotis D, Jiang Y, et al. Uncommon Candida species fungemia among cancer patients, Houston, Texas, USA[J]. Emerg Infect Dis, 2015,21(11):1942⁃1950. doi: 10.3201/eid2111.150404.
|
[22] |
Colombo AL, Júnior J, Guinea J. Emerging multidrug⁃resistant Candida species[J]. Curr Opin Infect Dis, 2017,30(6):528⁃538. doi: 10.1097/QCO.0000000000000411.
|
[23] |
Seth⁃Smith H, Büchler AC, Hinic V, et al. Bloodstream infection with Candida kefyr/Kluyveromyces marxianus: case report and draft genome[J]. Clin Microbiol Infect, 2020,26(4):522⁃524. doi: 10.1016/j.cmi.2019.11.014.
|
[24] |
Staab JF, Neofytos D, Rhee P, et al. Target enzyme mutations confer differential echinocandin susceptibilities in Candida kefyr[J]. Antimicrob Agents Chemother, 2014,58(9):5421⁃5427. doi: 10.1128/AAC.00096⁃14.
|
[25] |
Çuhadar T, Kalkancı A. Emerging pathogen: Candida kefyr (Kluvyeromyces marxianus)[J]. Mikrobiyol Bul, 2017,51(4):387⁃395. doi: 10.5578/mb.61813.
|
[26] |
Wang E, Farmakiotis D, Yang D, et al. The ever⁃evolving landscape of candidaemia in patients with acute leukaemia: non⁃susceptibility to caspofungin and multidrug resistance are associated with increased mortality[J]. J Antimicrob Chemother, 2015,70(8):2362⁃2368. doi: 10.1093/jac/dkv087.
|